ACLA
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion. Â
CMS to Revisit National Coverage Determination on NGS Tumor Testing
CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.
Healthcare Stakeholders Ask CMS Not to Limit Access to NGS Hereditary Cancer Risk Tests
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk
Premium
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.